RecruitingPhase 2NCT07230483
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.
Sponsor
Keymed Biosciences Co.Ltd
Enrollment
246 participants
Start Date
Dec 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.
Exclusion Criteria2
- Not enough washing-out period for previous therapy.
- Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALCM512
CM512 subcutaneous injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07230483
Related Trials
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT0710548855 locations
A Phase 1 Study of GS101 Injection
NCT074117551 location
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT0729839517 locations
Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis
NCT071469711 location
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT074536021 location